Effect of a MUC5AC Antibody (NPC-1C) Administered with Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

Brandon M. Huffman, Atrayee Basu Mallick, Nora K. Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A. Morse, Muhammad Shaalan Beg, Janet E. Murphy, Sharon Mavroukakis, Anjum Zaki, Benjamin L. Schlechter, Hanna Sanoff, Christopher Manz, Brian M. Wolpin, Philip Arlen, Jill Lacy, James M. Cleary

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of a MUC5AC Antibody (NPC-1C) Administered with Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences